Latest statistics and disclosures from Fairmount Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, ZGNX, AXSM, ARGX, IOVA, and represent 51.66% of Fairmount Funds Management's stock portfolio.
- Added to shares of these 10 stocks: ZGNX (+$9.8M), INSM (+$9.2M), CATB (+$8.5M), Therapeutics Acquisition Cor (+$8.4M), ARGX (+$5.3M), AXSM, AMRN, TIL, KROS, GBT.
- Reduced shares in these 5 stocks: MRTX (-$12M), MCRB (-$7.3M), TRIL, IOVA, ACAD.
- Sold out of its positions in MRTX, MCRB.
- Fairmount Funds Management was a net buyer of stock by $32M.
- Fairmount Funds Management has $243M in assets under management (AUM), dropping by 2.52%.
- Central Index Key (CIK): 0001802528
Tip: Access up to 7 years of quarterly data
Positions held by Fairmount Funds Management consolidated in one spreadsheet with up to 7 years of dataDownload as csv Download as Excel
Portfolio Holdings for Fairmount Funds Management
Companies in the Fairmount Funds Management portfolio as of the June 2021 quarterly 13F filing
|Company (Ticker)||Portfolio Weight||Valued At||Change in Shares||Share Count||Share Price|
|Insmed Com Par $.01 (INSM)||15.0||$37M||+33%||1.3M||28.46|
|Zogenix Com New (ZGNX)||14.0||$34M||+40%||2.0M||17.28|
|Axsome Therapeutics (AXSM)||8.7||$21M||+24%||313k||67.46|
|Argenx Se Sponsored Adr (ARGX)||8.6||$21M||+34%||69k||301.07|
|Iovance Biotherapeutics (IOVA)||5.4||$13M||-10%||506k||26.02|
|Instil Bio (TIL)||5.4||$13M||+22%||674k||19.32|
|Cogent Biosciences (COGT)||5.2||$13M||1.6M||8.11|
|Amarin Corp Spons Adr New (AMRN)||4.6||$11M||+57%||2.5M||4.38|
|ACADIA Pharmaceuticals (ACAD)||4.2||$10M||424k||24.39|
|Therapeutics Acquisition Cor Com Cl A||3.6||$8.9M||+1628%||864k||10.27|
|Trillium Therapeutics Com New (TRIL)||3.6||$8.7M||-32%||896k||9.70|
|Catabasis Pharmaceuticals In Com New (CATB)||3.5||$8.6M||+7596%||4.1M||2.11|
|Amicus Therapeutics (FOLD)||3.5||$8.6M||+12%||889k||9.64|
Setup an alert
Fairmount Funds Management will file the next quarterly 13-HR in about 2 months. Would you like to be notified?
|Enanta Pharmaceuticals (ENTA)||3.2||$7.8M||+4%||178k||44.01|
|Global Blood Therapeutics In (GBT)||3.0||$7.4M||+20%||210k||35.02|
|Keros Therapeutics (KROS)||2.6||$6.3M||+36%||149k||42.47|
|Miragen Therapeutics (VRDN)||0.3||$642k||35k||18.29|
|Verona Pharma Sponsored Ads (VRNA)||0.2||$549k||84k||6.54|
Past Filings by Fairmount Funds Management
SEC 13F filings are viewable for Fairmount Funds Management going back to 2019
- Fairmount Funds Management 2021 Q2 filed Aug. 13, 2021
- Fairmount Funds Management 2021 Q1 filed May 14, 2021
- Fairmount Funds Management 2020 Q4 filed Feb. 12, 2021
- Fairmount Funds Management 2020 Q3 filed Nov. 12, 2020
- Fairmount Funds Management 2020 Q2 filed Aug. 4, 2020
- Fairmount Funds Management 2020 Q1 filed May 8, 2020
- Fairmount Funds Management 2019 Q4 filed Feb. 12, 2020